Common Reference-Based Tandem Mass Tag Multiplexing for the Relative Quantification of Peptides: Design and Application to Degradome Analysis of Diphtheria Toxoid.

degradomics diphtheria toxoid enzyme kinetics proteomics tandem mass tag multiplexing vaccine quality control

Journal

Journal of the American Society for Mass Spectrometry
ISSN: 1879-1123
Titre abrégé: J Am Soc Mass Spectrom
Pays: United States
ID NLM: 9010412

Informations de publication

Date de publication:
02 Jun 2021
Historique:
pubmed: 14 5 2021
medline: 15 12 2021
entrez: 13 5 2021
Statut: ppublish

Résumé

Currently, animal tests are being used to confirm the potency and lack of toxicity of toxoid vaccines. In a consistency approach, animal tests could be replaced if production consistency (compared to known good products) can be proven in a panel of in vitro assays. By mimicking the in vivo antigen processing in a simplified in vitro approach, it may be possible to distinguish aberrant products from good products. To demonstrate this, heat-exposed diphtheria toxoid was subjected to partial digestion by cathepsin S (an endoprotease involved in antigen processing), and the peptide formation/degradation kinetics were mapped for various heated toxoids. To overcome the limitations associated with the very large number of samples, we used common reference-based tandem mass tag (TMT) labeling. Instead of using one label per condition with direct comparison between the set of labels, we compared multiple labeled samples to a common reference (a pooled sample containing an aliquot of each condition). In this method, the number of samples is not limited by the number of unique TMT labels. This TMT multiplexing strategy allows for a 15-fold reduction of analysis time while retaining the reliability advantage of TMT labeling over label-free quantification. The formation of the most important peptides could be followed over time and compared among several conditions. The changes in enzymatic degradation kinetics of diphtheria toxoid revealed several suitable candidate peptides for use in a quality control assay that can distinguish structurally aberrant diphtheria toxoid from compliant toxoids.

Identifiants

pubmed: 33983728
doi: 10.1021/jasms.1c00070
pmc: PMC8176455
doi:

Substances chimiques

Diphtheria Toxoid 0
Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1490-1497

Références

Sci Rep. 2020 Jul 14;10(1):11535
pubmed: 32665578
Biotechniques. 2002 Oct;33(4):924-30
pubmed: 12398202
J Exp Med. 2006 Sep 4;203(9):2049-55
pubmed: 16908625
Anal Chem. 2019 Dec 17;91(24):15941-15950
pubmed: 31738517
Vaccines (Basel). 2020 Dec 01;8(4):
pubmed: 33271767
Immunol Lett. 2012 Sep;147(1-2):55-62
pubmed: 22732235
Allergy. 2011 Aug;66(8):1005-13
pubmed: 21352239
Nat Commun. 2020 Jan 27;11(1):532
pubmed: 31988290
Cell. 2020 Feb 20;180(4):729-748.e26
pubmed: 32059776
Biochemistry. 1996 Feb 20;35(7):2374-9
pubmed: 8652579
Clin Biochem. 2013 Apr;46(6):444-55
pubmed: 23041077
J Proteome Res. 2013 Apr 5;12(4):1898-908
pubmed: 23410224
Mol Cell Proteomics. 2017 May;16(5):873-890
pubmed: 28325852
Sci Rep. 2015 Aug 03;5:12707
pubmed: 26235974
Allergy. 2012 Nov;67(11):1375-82
pubmed: 22973879
J Biol Chem. 1979 Jul 10;254(13):5838-42
pubmed: 221484
Nat Med. 2010 Nov;16(11):1333-40
pubmed: 21037588
PLoS One. 2014 Aug 15;9(8):e104520
pubmed: 25126882
Science. 2005 Mar 11;307(5715):1630-4
pubmed: 15761154
J Allergy Clin Immunol. 2016 May;137(5):1525-34
pubmed: 26559323
Vaccine. 2021 Apr 28;39(18):2506-2516
pubmed: 33824038
J Pharm Sci. 2020 Jan;109(1):543-557
pubmed: 31678246
PLoS One. 2011 Feb 16;6(2):e17278
pubmed: 21359181
J Proteome Res. 2014 Dec 5;13(12):5293-309
pubmed: 25337643
Anal Chem. 2019 Jan 2;91(1):178-189
pubmed: 30525468
J Allergy Clin Immunol. 2015 Jul;136(1):151-8
pubmed: 25670010
Anal Chem. 2003 Apr 15;75(8):1895-904
pubmed: 12713048
Vaccine. 2003 Dec 12;22(2):156-67
pubmed: 14615142

Auteurs

Thomas J M Michiels (TJM)

Division of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, 2333 CC Leiden, The Netherlands.
Intravacc, Institute for Translational Vaccinology, 3721 MA Bilthoven, The Netherlands.

Madelief A van Veen (MA)

Division of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, 2333 CC Leiden, The Netherlands.

Hugo D Meiring (HD)

Intravacc, Institute for Translational Vaccinology, 3721 MA Bilthoven, The Netherlands.

Wim Jiskoot (W)

Division of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, 2333 CC Leiden, The Netherlands.

Gideon F A Kersten (GFA)

Division of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, 2333 CC Leiden, The Netherlands.
Intravacc, Institute for Translational Vaccinology, 3721 MA Bilthoven, The Netherlands.

Bernard Metz (B)

Intravacc, Institute for Translational Vaccinology, 3721 MA Bilthoven, The Netherlands.

Articles similaires

Animals Huntington Disease Mitochondria Neurons Mice
Calcium Carbonate Sand Powders Construction Materials Materials Testing
Cicer Germination Proteolysis Seeds Plant Proteins

Classifications MeSH